- Home
- BLTE vs ERO Comparison
BLTE vs ERO Comparison
Compare BLTE & ERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLTE | ERO |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 2.8B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLTE | ERO |
|---|---|---|
| Price | $173.05 | $35.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $198.00 | $36.50 |
| AVG Volume (30 Days) | 198.1K | ★ 1.5M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $51.94 |
| Revenue Next Year | $492.11 | $2.43 |
| P/E Ratio | ★ N/A | $22.61 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $65.00 | $16.37 |
| 52 Week High | $200.00 | $40.83 |
Technical Indicators
Market Signals| Indicator | BLTE | ERO |
|---|---|---|
| Relative Strength Index (RSI) | 54.90 | 49.98 |
| Support Level | $167.80 | $24.04 |
| Resistance Level | $182.61 | $36.25 |
| Average True Range (ATR) | 7.90 | 1.83 |
| MACD | 2.18 | -0.50 |
| Stochastic Oscillator | 48.43 | 11.75 |
Price Performance
Historical ComparisonAbout BLTE Belite Bio Inc
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
About ERO Ero Copper Corp.
Ero Copper Corp is a high-margin, high-growth copper producer with operations in Brazil. Its primary asset is its 99.6% ownership interest in Mineracao Caraiba S.A., held indirectly through its wholly-owned subsidiary. The company also owns a 97.6% ownership interest in NX Gold S.A. indirectly through its wholly-owned subsidiary. Its reporting segments include its three operating mines in Brazil, the Caraiba Operations, the Tucuma Operation, and the Xavantina Operations, and its corporate head office in Canada.